Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite presented as an injectable solution for intramuscular, intravenous, or subcutaneous use. It is employed to manage autoimmune disorders and certain cancers, reducing abnormal cell proliferation and immune activity in adult patients.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant units and pharmacies worldwide, ensuring quality‑controlled batches and regulatory compliance for global distribution.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and plaque formation. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: impedes tumor growth and improves survival outcomes.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Mucositis or mouth ulcers. - Alopecia (hair loss). - Elevated liver enzymes. - Mild cytopenias (low blood counts).

Serious or Rare Side Effects: - Pulmonary fibrosis or interstitial pneumonitis. - Severe hepatotoxicity or liver failure. - Bone marrow aplasia leading to profound cytopenias. - Life‑threatening infections due to immunosuppression. - Renal toxicity or acute kidney injury. - Teratogenic effects causing fetal malformations.

Before initiating therapy, clinicians should evaluate several safety parameters. - Renal function: assess baseline creatinine and monitor because the drug is renally excreted. - Liver function: perform regular transaminase tests to detect hepatotoxicity. - Hematology: conduct frequent complete blood counts to identify cytopenias. - Pregnancy: avoid use due to known teratogenic potential. - Infection risk: screen for latent infections and vaccinate appropriately before treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its toxicity or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins (e.g., ampicillin): reduce renal clearance, raising drug levels. - Proton pump inhibitors: may elevate systemic exposure. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Sulfasalazine: additive bone‑marrow suppression. - Azathioprine: combined immunosuppressive effect. - Trimethoprim: may increase methotrexate toxicity.